SEC Company Response from Inmune Bio, Inc. (INMB) (CIK 0001711754) (INMB) — Mar 31, 2020
Inmune Bio, Inc. (INMB) (CIK 0001711754)
Date: March 31, 2020 · CIK: 0001711754 · Accession: 0001213900-20-008226
AI Filing Summary & Sentiment
File numbers found in text: 333-237368
Letter
Re: INmune Bio Inc. (the “Company”)
March 31, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
File No. 333-237368
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. on April 2, 2020 or as soon thereafter as is practicable.
Very truly yours,
INMUNE BIO INC.
Show Raw Text
CORRESP
1
filename1.htm
March
31, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: INmune Bio Inc. (the “Company”)
Registration Statement on Form S-3
File No. 333-237368
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective
date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. on April
2, 2020 or as soon thereafter as is practicable.
Very truly yours,
INMUNE BIO INC.
By:
/s/ David Moss
David
Moss
Chief Financial Officer